Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermazulen is a topical pharmaceutical ointment containing a combination of guaiazulene and chamomile oil. Developed by the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague, it is widely used for its anti-inflammatory, anti-allergic, and antiseptic properties. The active ingredient, guaiazulene, is a dark blue sesquiterpene derivative obtained from chamomile (Matricaria chamomilla) that promotes skin healing and reduces irritation by inhibiting the release of inflammatory mediators. It is primarily indicated for the treatment of minor skin injuries, burns, eczema, and other inflammatory skin conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermazulen.